Reckitt Benckiser Group (LON:RB) has been assigned a GBX 7,700 ($100.61) target price by Barclays in a research report issued on Thursday, September 26th, Borsen Zeitung reports. The firm presently has a “buy” rating on the stock. Barclays‘s target price would indicate a potential upside of 26.33% from the stock’s current price.
Other equities research analysts have also recently issued reports about the company. Royal Bank of Canada reaffirmed an “underperform” rating and issued a GBX 5,900 ($77.09) price objective on shares of Reckitt Benckiser Group in a research note on Monday, August 5th. Sanford C. Bernstein set a GBX 8,100 ($105.84) price objective on Reckitt Benckiser Group and gave the company a “buy” rating in a research note on Wednesday, September 18th. Credit Suisse Group set a GBX 5,800 ($75.79) price objective on Reckitt Benckiser Group and gave the company a “sell” rating in a research note on Wednesday, July 31st. Shore Capital reaffirmed an “under review” rating on shares of Reckitt Benckiser Group in a research note on Tuesday, July 30th. Finally, UBS Group set a GBX 6,500 ($84.93) price objective on Reckitt Benckiser Group and gave the company a “neutral” rating in a research note on Thursday, September 19th. Four analysts have rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the company’s stock. Reckitt Benckiser Group presently has a consensus rating of “Hold” and an average price target of GBX 7,021.76 ($91.75).
RB stock traded down GBX 80 ($1.05) during midday trading on Thursday, hitting GBX 6,095 ($79.64). 1,306,287 shares of the company’s stock were exchanged, compared to its average volume of 1,720,000. The business has a 50-day simple moving average of GBX 6,286.48 and a two-hundred day simple moving average of GBX 6,285.71. The company has a current ratio of 0.59, a quick ratio of 0.43 and a debt-to-equity ratio of 85.08. The stock has a market capitalization of $43.24 billion and a PE ratio of 30.60. Reckitt Benckiser Group has a 1-year low of GBX 5,559 ($72.64) and a 1-year high of GBX 6,862 ($89.66).
In other news, insider Adrian Nevil Hennah sold 81,063 shares of the business’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of GBX 6,399 ($83.61), for a total value of £5,187,221.37 ($6,778,023.48).
About Reckitt Benckiser Group
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands.
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.